Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) - Net Assets
Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) has net assets worth €253.42 Million EUR (≈ $296.28 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€457.93 Million ≈ $535.36 Million USD) and total liabilities (€204.50 Million ≈ $239.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EUZ PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €253.42 Million |
| % of Total Assets | 55.34% |
| Annual Growth Rate | 8.98% |
| 5-Year Change | 31.63% |
| 10-Year Change | 130.22% |
| Growth Volatility | 7.0 |
Eckert & Ziegler Strahlen- und Medizintechnik AG - Net Assets Trend (2013–2025)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see EUZ stock market capitalisation.
Annual Net Assets for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2025)
The table below shows the annual net assets of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2025. Also explore EUZ shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €253.42 Million ≈ $296.28 Million |
+12.53% |
| 2024-12-31 | €225.21 Million ≈ $263.30 Million |
+0.50% |
| 2023-12-31 | €224.09 Million ≈ $261.99 Million |
+4.90% |
| 2022-12-31 | €213.63 Million ≈ $249.75 Million |
+10.96% |
| 2021-12-31 | €192.53 Million ≈ $225.08 Million |
+29.28% |
| 2020-12-31 | €148.92 Million ≈ $174.10 Million |
+6.80% |
| 2019-12-31 | €139.44 Million ≈ $163.02 Million |
+12.56% |
| 2018-12-31 | €123.88 Million ≈ $144.83 Million |
+5.41% |
| 2017-12-31 | €117.52 Million ≈ $137.39 Million |
+6.76% |
| 2016-12-31 | €110.08 Million ≈ $128.69 Million |
+5.17% |
| 2015-12-31 | €104.67 Million ≈ $122.37 Million |
+10.77% |
| 2014-12-31 | €94.49 Million ≈ $110.47 Million |
+4.68% |
| 2013-12-31 | €90.27 Million ≈ $105.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Eckert & Ziegler Strahlen- und Medizintechnik AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 482.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €166.33 Million | 66.07% |
| Other Components | €85.43 Million | 33.93% |
| Total Equity | €251.77 Million | 100.00% |
Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Market Cap
The table below lists competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Janux Therapeutics Inc
NASDAQ:JANX
|
$878.78 Million |
|
Beijing Qianjing Landscape Co
SHG:603778
|
$878.92 Million |
|
VNDIRECT Securities Corp
VN:VND
|
$879.14 Million |
|
IPERIONX LTD SP.ADR/10
F:30Z0
|
$879.39 Million |
|
Elevra Lithium Limited
AU:ELV
|
$878.58 Million |
|
PixArt Imaging
TWO:3227
|
$878.58 Million |
|
Mingyue Optical Lens Co.Ltd.
SHE:301101
|
$878.43 Million |
|
Yunnan QuakeSafe Seismic Isolation Technologies Co Ltd Class A
SHE:300767
|
$878.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eckert & Ziegler Strahlen- und Medizintechnik AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 223,450,000 to 251,767,000, a change of 28,317,000 (12.7%).
- Net income of 48,763,000 contributed positively to equity growth.
- Dividend payments of 10,428,000 reduced retained earnings.
- Share repurchases of 638,000 reduced equity.
- Other factors decreased equity by 9,380,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €48.76 Million | +19.37% |
| Dividends Paid | €10.43 Million | -4.14% |
| Share Repurchases | €638.00K | -0.25% |
| Other Changes | €-9.38 Million | -3.73% |
| Total Change | €- | 12.67% |
Book Value vs Market Value Analysis
This analysis compares Eckert & Ziegler Strahlen- und Medizintechnik AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.26x to 2.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.31 | €12.01 | x |
| 2018-12-31 | €6.06 | €12.01 | x |
| 2019-12-31 | €6.71 | €12.01 | x |
| 2020-12-31 | €7.18 | €12.01 | x |
| 2021-12-31 | €9.03 | €12.01 | x |
| 2022-12-31 | €10.20 | €12.01 | x |
| 2023-12-31 | €3.56 | €12.01 | x |
| 2024-12-31 | €10.72 | €12.01 | x |
| 2025-12-31 | €4.02 | €12.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eckert & Ziegler Strahlen- und Medizintechnik AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.37%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.63%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.82x
- Recent ROE (19.37%) is above the historical average (13.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 10.82% | 7.71% | 0.66x | 2.14x | €685.80K |
| 2014 | 7.65% | 5.32% | 0.68x | 2.11x | €-2.08 Million |
| 2015 | 10.75% | 7.67% | 0.71x | 1.97x | €748.50K |
| 2016 | 9.08% | 6.92% | 0.69x | 1.90x | €-969.00K |
| 2017 | 13.09% | 10.60% | 0.64x | 1.93x | €3.47 Million |
| 2018 | 13.15% | 9.56% | 0.74x | 1.87x | €3.87 Million |
| 2019 | 15.93% | 12.34% | 0.65x | 1.98x | €8.20 Million |
| 2020 | 15.48% | 12.99% | 0.60x | 1.98x | €8.10 Million |
| 2021 | 18.43% | 19.14% | 0.52x | 1.86x | €15.79 Million |
| 2022 | 13.81% | 13.17% | 0.53x | 1.97x | €8.07 Million |
| 2023 | 11.84% | 10.69% | 0.56x | 1.98x | €4.08 Million |
| 2024 | 14.89% | 11.25% | 0.67x | 1.98x | €10.93 Million |
| 2025 | 19.37% | 15.63% | 0.68x | 1.82x | €23.59 Million |
Industry Comparison
This section compares Eckert & Ziegler Strahlen- und Medizintechnik AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $37,307,353,473
- Average return on equity (ROE) among peers: -16.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | €253.42 Million | 10.82% | 0.81x | $878.60 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.76 Billion | 5.42% | 0.47x | $157.40K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $28.30 Million |
| Medtronic PLC (2M6) | $1.33 Billion | 22.02% | 0.46x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $1.86 Billion | -10.94% | 0.43x | $401.71 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $18.88 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.22 Billion | -2.23% | 0.20x | $107.57 Million |
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more